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PURPOSE. Retinal ischemia has been traditionally assessed by fluorescein angiography,
visualizing perfused vessels. However, this method does not provide any information about
nonperfused vessels, and although it is often assumed that vessels in ischemic areas regress,
we know little about how nonperfused retinal vessels change over time. Here, we aim to learn
more about the long-term fate of nonperfused vessels in the retinal vasculature.
METHODS. Optical coherence tomography (OCT) was used to visualize perfusion as well as
structural properties of the retinal vasculature in patients suffering from retinal vascular
occlusions. In addition, postmortem tissue from a patient with long standing (6 years) central
retinal vein occlusion (CRVO) was investigated, using immunohistochemistry on whole-
mount retina and paraffin sections to visualize blood vessel components.
RESULTS. Comparing OCT angiography with enface OCT images revealed that in ischemic areas
of the retina, nonperfused, larger vessels could be detected as hyperreflective structures in
enface OCT images. Furthermore, analysis of a postmortem tissue sample from a CRVO
patient with a large nonperfused region in the macula, revealed preservation of the basement
membrane from all retinal vessels, including nonperfused, acellular vessels of all calibers.
CONCLUSIONS. Our data suggests long-term preservation of vascular basement membrane in
ischemic retina. This has implications for therapeutic approaches aiming to alleviate retinal
ischemia via the regeneration of damaged vessels.
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Loss of perfusion to the retinal vasculature can lead toischemia and consequent vision loss in several diseases,
most notably in retinal vascular diseases such as retinal vein
occlusion (RVO) and diabetic retinopathy. Retinal vein occlu-
sion can cause significant ocular morbidity and is a common
cause for significant visual loss among the elderly with a
worldwide prevalence of 16 million.1 The clinical classification
of central, hemi, and branch RVO is based upon the location of
vascular sequelae in the retina and the site of thrombus within
the retinal vascular tree.2 In central retinal vein occlusion
(CRVO), this occurs in the main trunk of the central retinal vein
either at, or proximal to the lamina cribrosa.2 In branch retinal
vein occlusion (BRVO), the blockage occurs distal to the first-
order bifurcation of the retinal vein at sites of arteriovenous
crossings, where the arteriole and vein share a common
adventitial sheath.3,4
While the pathogenesis of RVO and its subtypes have been
evidenced by several clinicopathological series, its pathophys-
iology is less clear.2,5 Nonetheless, some insight into the impact
of nonperfusion itself on downstream vascular cells has been
gained by a primate study based on experimental BRVO using
an argon laser to occlude vessels.6 This led to rapid
degenerative changes (onset within hours) resulting in an
almost complete loss of capillary endothelial cells and pericytes
(within 1–3 weeks), with only empty basement membrane
sleeves remaining. There was no evidence of recanalization. In
contrast, a similar study (also in primates) showed recanaliza-
tion of some basement membrane tubes.7 Similarly, the largest
histopathological study in humans to date (29 eyes), observed
that recanalization can occur, but in this instance this was
found only in the thrombi of the large central retinal veins.2
Clinically, there is limited evidence for reperfusion of retinal
vessels. Nevertheless, one clinical study has observed a
reduction in areas of ‘‘retinal nonperfusion’’ on ultra widefield
fluorescein angiograms (FA) on a small proportion (<10%) of
31 patients with BRVO receiving anti-VEGF intravitreal injec-
tions.8
Functional recovery of previous perfusion paths via the
repopulation of empty basement membrane tubes with
migrating endothelial cells and pericytes from neighboring,
intact vessel regions, might be possible as long as the vascular
basement membrane persists. However, how long and in what
shape empty basement membrane tubes survive in the retina is
not well understood and may depend on the specific
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circumstance. For instance, Ashton described in a classic study
that only very delicate, acellular strands remained after
hyperoxia-induced capillary closure in kittens.9 Similarly, we
have shown transient, thin, collagen IV–positive strands in
developing mouse retina after hyperoxia induced capillary
obliteration.10 In contrast, in mature retina the basement
membrane is more substantial9 and was found to persist up to
40 days in an ischemia/reperfusion model in cat.11
However, the natural history of nonperfused vessels and the
long-term fate of empty basement membrane tubes in human
pathology is poorly understood. This is largely due to the
limitation of retinal imaging modalities for the visualization of
nonperfused vessels. Although larger, nonperfused vessels can
be seen on fundus photographs as ghost vessels (especially
superficial ones), smaller or deeper nonperfused vessels have
so far been invisible. The mainstay of imaging retinal vessels
has been fluorescein angiography, which, by definition, only
allows visualization of perfused vessels. But this has changed
with the advent of optical coherence tomography (OCT)-based
technology. Using enface imaging, and OCT angiography, we
can now for the first time, delineate nonperfused retinal
vessels in vivo. In this study, we demonstrate the feasibility of
imaging nonperfused vessels using enface OCT and OCT
angiography in patients with BRVO. We further provide
clinicohistologic evidence, from a case of CRVO, for long-term
basement membrane persistence in the entire retinal vascula-
ture plexus.
MATERIALS AND METHODS
OCT Angiography and Enface OCT Imaging of
BRVO Patients
All OCT angiography and enface OCT images were acquired
and analyzed using the RTVue XR Avanti Spectral Domain OCT
(Optovue, Inc., Fremont, CA, USA), using methodology
described elsewhere.12 The equipment was used to obtain
and select good quality OCT angiograms (showing blood flow)
and the corresponding enface OCT images (representing
frontal sections of retinal layers) for multimodal analysis.
Institutional review board (IRB) approval for the review of
these patient records has been obtained at our institutions.
CRVO Eye Tissue Donor
The medical history includes asthma, emphysema, carcinoid
tumor, atrial septal defect, and two right-sided cardiac stents.
Medication included warfarin, prednisone, spironolactone,
digoxin, fluticasone/salmeterol, tiotropium, salbutamol, inda-
pamide, mirtazapine, simvastatin, and lactulose. Institutional
review board/ethic committee approvals for the review of this
patient’s records and the analysis of the postmortem eye tissue
have been obtained at our institutions.
Tissue Processing
The time elapsed between death and fixation of the eyes in this
study was 3.5 hours. The eyes were fixed in 4% paraformal-
dehyde (PFA) for 64 hours and then kept in 1% PFA for 3
weeks. Subsequently, the anterior parts of the eyes were
removed and the eyes were flattened (using four radial
incisions) and photographed. A region that included the optic
disc and fovea was dissected and processed for wax
embedding. Because in one of our previously studied
samples,13 the retina split horizontally during embedding we
used here a soft sponge to stabilize the tissue and apply gentle
pressure during wax processing. Once embedded, nasotem-
poral sections were cut at 6 lm and mounted onto Superfrost
plus slides (VWR International Ltd., Lutterworth, UK). Sections
were deparaffinized with xylene and rehydrated through
graded alcohols and processed for immunohistochemistry.
Immunohistochemistry
Antigen retrieval was carried out by heating the slides to 1258C
in 90% glycerol (molecular grade) and 10% 0.01M citrate buffer
pH 6.0 for 20 minutes in a pressure cooker. Sections were then
briefly washed in water, incubated for 1 hour at room temper-
ature in blocking buffer (1% BSA, 0.5% triton X-100 in PBS) and
then in primary antibody (diluted 1:200 in blocking buffer)
either at room temperature for 1 hour or overnight at 48C.
Primary antibodies used were: rabbit anti-collagen IV (2150-
0140; AbD Serotec, Kidlington, UK), goat anti-endoglin
(AF1097; R&D systems, Minneapolis, MN, USA), mouse anti
vimentin-Cy3 (C9080; Sigma-Aldrich, St. Louis, MO, USA), goat
anti-GFAP (C9205; Sigma-Aldrich), mouse anti-alpha smooth
muscle actin-Cy3 (C6198; Sigma-Aldrich). Sections were
washed in washing buffer (0.1% tween20 in PBS) and incu-
bated for 1 hour at room temperature in secondary antibodies
(diluted 1:200 in blocking buffer; Invitrogen, Thermo Fisher
Scientific, Waltham, MA, USA). Subsequently sections were
washed in washing buffer, treated with Hoechst (10 lg/ml in
washing buffer) for 30 seconds, washed again and mounted in
Moviol mounting medium (Sigma-Aldrich). Images were taken
using a Leica DM IRB fluorescent microscope (Leica, Hicks-
ville, NY, USA) and/or a Zeiss LSM700 confocal microscope
(Zeiss, Jena, Germany).
RESULTS
Vascular Structures in Ischemic Retina
In order to learn more about the relationship between
vascular structures and vascular perfusion, we compared FA,
OCT angiography, and enface OCT images from BRVO patients.
Three selected chronic BRVO patients (15, 44, and 60 months
since occlusion) are shown in Figure 1. In patient 1 (Figs. 1A,
1D, 1D’) and in patient 2 (Figs. 1B, 1E, 1E’) FAs and OCT
angiography were recorded on the same day and nonperfused
areas correspond well in the two imaging modalities. In
patient 3 (Figs. 1C, 1F, 1F’) the FA was taken 5 years earlier and
shows a cluster of vessels (arrow in Fig. 1C) that is no longer
perfused in the angiography OCT (Fig. 1F). In all three
patients, the Enface OCT (Figs. 1D’, 1E’, 1F’) revealed vascular
structures (ghost vessels) in nonperfused areas that appeared
similar to vessels in perfused areas, with regards to signaling
intensity as well as network patterning (arrows in Fig. 1),
suggesting vessels may maintain light scattering properties in
OCT in the absence of perfusion. Notably, the ghost vessels
seen in patient 3 (arrow Fig. 1F’) show the same pattern as the
still perfused vessels in the FA 5 years earlier (arrow Fig. 1C).
We hypothesize that the OCT signal of ghost vessels originates
from remaining basement membrane. To establish in more
detail, the anatomical basis of this OCT signal, we carried out a
histologic study on a postmortem sample from a CRVO
patient.
Clinical Features of CRVO Tissue Donor
The female donor died from respiratory failure in January 2013,
at age 81. She presented in June 2008 with deteriorating left
central vision (VA 20/50 due to nonischemic CRVO). She was
treated with an intraocular Avastin injection, to which she
responded well (VA 20/26 a month later) and monthly
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injections were continued (for a total of 41 injections).
Fluorescein angiography at the initial visit showed a small
ischemic region around the fovea (Fig. 2A). This ischemic
region progressively expanded over the next 4.5 years up to
the point of death (Fig. 2B, 2C). During this period recurrent
cystoid edema ensued (Figs. 2D–I), accompanied by progres-
sive thinning of the retina that roughly correlated with the
expansion of the ischemic area (Figs. 2J–L).
FIGURE 1. Fluorescein angiography (A–C), OCT angiography (D–F) and enface OCT (D’–F’) imaging in three BRVO patients reveals vascular
structures (white arrows) in nonperfused regions that have similar signal intensity and patterning to vessels in perfused areas. Fluorescein
angiography and OCT imaging was done on the same day in patient 1 and 2. In patient 3 the FA has been taken 5 years earlier.
FIGURE 2. Clinical data from the CRVO eye donor. Fluorescein angiograms illustrate the appearance and enlargement of nonperfused areas over 5
years (A–C). During this time the patient received regular anti-VEGF injections with reoccurring edema (D–I), which was accompanied by a
progressive thinning of the retina in nonperfused areas (J–L).
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Postmortem Histology on Retinal Whole Mount
We dissected a sample including the optic nerve and the
macula from the fixed eye and used an anti-collagen IV
antibody to visualize basement membrane in whole-mount
immunohistochemistry. Remarkably, this revealed the pattern
of a complete retinal vasculature (Fig. 3A). We use the last
available angiogram from the patient (Fig. 3B), which was
obtained 3 weeks before death, to compare the basement
membrane network with actual perfusion (Fig. 3C). This
showed that in this patient there was no correlation between
the external appearance of the retinal vessel basement
membrane and the internal perfusion of the vessel.
Matching Perfusion With Vessel Histology
In order to learn more about the lumen of the retinal vessels,
we cut serial wax sections from the entire tissue sample. To
correlate the sections with the images from the whole-mount
stain and the ante-mortem FA, we used the distribution of large
blood vessels within individual sections to spatially map all
sections as previously described.13,14 This is illustrated in
Figure 4A where the nasaltemporal location of vessels (red dots
in Fig. 4A) is marked on every 20th section (yellow lines in Fig.
4A). This allowed us to follow an individual vascular path in
cross sections. Immunohistochemistry with antibodies against
collagen IV (red, labelling basement membrane) and endoglin
(green, labelling endothelial cells) showed that endothelial
cells were completely absent from the profile of a small,
nonperfused arteriole near the fovea (Fig. 4B–D). No endoglin
staining could be found either in a partially perfused section of
the vessel further upstream (Figs. 4B, 4E). However, in well-
perfused sectors of the artery, further upstream, strong
endoglin staining indicated the presence of a complete
endothelium (Figs. 4B, 4F, 4G). Mapping the presence or
absence of endoglin staining on sections throughout the
macula showed spatial correlation with perfusion in the
angiogram (Fig. 4H).
Thickening of Vessel Walls
In Figures 4F, 4G it is noticeable that the collagen IV–positive
basement membrane appears abnormally thick. We therefore
compared the vessel walls from the affected eye and the
unaffected contralateral eye. The main vessels near the optic
nerve head (Fig. 5A–F) displayed a markedly thickened tunica
media in the affected eye (Figs. 5B, 5E, 5F). This appears to
have increased the stiffness of the vessels as veins in the
FIGURE 3. Immunohistochemistry visualizing collagen IV on postmor-
tem tissue from the CRVO patient shows the pattern of an intact retinal
vasculature (A). Mapping against the FA (taken 3 weeks before death)
shows that basement membrane persists in nonperfused vessels (B–C).
FIGURE 4. The position of larger vessels (red dots) in serial wax
sections (yellow lines) was mapped onto the angiogram and collagen
IV–stained whole mount (A). Immunohistochemistry to visualize
endothelial cells (endoglin in green) and basement membrane
(collagen IV in red) along the path of an arteriole (B) shows an intact
endothelium in well-perfused sectors but a lack of endothelial cells in
partial- or nonperfused sectors (C–G). Mapping the distribution of
endoglin staining within vessels (in green for intact, yellow partial, and
red absent staining) onto the angiogram shows a spatial correlation
between the nonperfusion and the absence of endothelial cells (H).
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FIGURE 5. Comparison of vessel walls from the unaffected (A, C, D, G, I) and the affected eye (B, E, F, H, J) show increased vessel wall thickness
and decreased lumen sizes. Basement membrane is stained in red (collagen IV) and smooth muscle cells in green (smooth muscle actin). Larger
vessels are shown in A–F (white boxes in A, B indicate magnified details in C–F). Arteries are indicated by A and veins by V. Smaller vessels and
capillaries are shown in G–J in the central (G, H) and the peripheral (I, J) retina. There is an absence of smooth muscle cells in the nonperfused,
central region in the affected eye (H). Measuring lumen size in the corresponding FA (K, L) in a ring-shaped area around the optic disc (indicated
by red ring), confirmed the decreased lumens in vivo in the affected eye (M). The number of vessel lumens counted, of a certain diameter
(measured in arbitrary units) are shown in orange for the unaffected and in blue bars for the affected eye. Visualization of glial cells in the affected
eye (N, O) shows Mu¨ller cells in red (vimentin), retinal astrocytes in green (GFAP), and vessel basement membranes in white (collagen IV). Vessels
in a still perfused area (between optic disc and fovea) show vimentin positive endothelial cells in their lumen (N), whereas vessels in the
nonperfused area (temporal to fovea) do not contain vimentin positive structures (Mu¨ller cells or endothelial cells) within their lumen (O).
Autofluorescent red blood cells (in green) can be seen inside and outside vessels (white arrows in [O]).
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affected eye maintained a circular shape in cross sections (Fig.
5B), in contrast to the collapsed appearance in the contralat-
eral eye (Fig. 5A). However, the hypertrophic tunica media
contained only marginally more a-smooth muscle actin (a-
SMA)–positive cells. Increased collagen deposition was also
found in smaller vessels (Figs. 5G–J). In nonperfused areas
small vessels did not contain any smooth muscle cells (Fig. 5H),
suggesting that not only endothelial cells but also mural cells
have died in these regions.
The thickened vessel walls appear to result in decreased
lumen diameters (Figs. 5A, 5B, 5I, 5J). To test whether lumens
were also reduced in vivo, we measured the diameter of vessels
around the optic disc in the FA that were obtained 3 weeks
before the patient’s death. This showed that calibers were
larger in the contralateral eye (Figs. 5K, 5M) compared with
the CRVO eye (Figs. 5L, 5M). Continuous narrowing of the
lumen may lead to occlusion, but the vast majority of the
vascular structures still had a lumen remaining. To assess
whether glial cells invading the vessel lumen may have
contributed to occlusions, as has been previously suggest-
ed,15,16 we visualized Mu¨ller cells and retinal astrocytes (Figs.
5N, 5O) in the CRVO eye by staining for vimentin and glial
fibrillary acidic protein (GFAP). In perfused retina, endothelial
cells (which also express vimentin) can be seen lining the
vessel lumen (Fig. 5N). In contrast, in nonperfused retina we
could not find any vimentin- or GFAP-positive structures (Fig.
5O), demonstrating the absence of endothelial cells, Mu¨ller
cells, and retinal astrocytes inside the vascular lumen (Fig. 5O).
On the other hand, autofluorescent, red blood cells (arrows in
Fig. 5O) could be seen occasionally inside vessel lumens, but it
is not clear whether these represent obstructions in the living
patient or whether they may have pooled postmortem.
DISCUSSION
In the enface OCT images from the three BRVO patients
presented in this study, we could identify vascular structures in
nonperfused regions of the retinal vasculature. At this point, it
is not possible to establish with certainty which anatomic
structures within nonperfused vessels have sufficient light
scattering properties to generate this OCT signal. However, a
previous OCT study on large vessels around the optic disc has
shown hyper scattering from the upper and lower edge of
vessels, which could also be found in an occluded vein in a
BRVO patient, strongly suggesting that the enface OCT signal
originates from the vessel wall.17
Whether in our BRVO patients the nonperfused vascular
structures still contained living endothelial cells or pericytes
is not known, but in our clinicopathological CRVO case study
there was a clear correlation between nonperfusion and lack
of endothelial cells. Furthermore, there was also a lack of
smooth muscle cells in the ischemic region and most vessels
appeared to be acellular, suggesting also a loss of pericytes.
This is in line with observations in model system where
vascular occlusion has led to rapid loss of endothelial cells
and pericytes.6,7,11,18,19 Our CRVO patient converted from
nonischemic to ischemic RVO, which occurs frequently in
nonischemic cases.20–24 The nonperfused area slowly ex-
panded over the course of several years, suggesting a
progressive loss of vascular cells over time. The remaining
acellular basement membrane tubes, however, were pre-
served for many years. It therefore seems possible that the
nonperfused vascular structures seen in the enface OCT are
basement membrane remnants from occluded vessels.
Acellular basement membrane tubes have been referred to
by numerous investigators as ‘‘string’’ vessels (extensively
review by WR Brown25), but this term tends to describe
structures that are significantly thinner than the original
vessels. In contrast, the outer diameter of the collagen IV–
positive basement membrane tubes in our CRVO case study
were similar to normal vessels, and the term ‘‘string’’ vessels
may therefore not be appropriate here. Although it is known
that the basement membrane in the retinal vasculature
becomes progressively thicker with age,26–29 the thickening
of basement membranes in our CRVO case was much more
substantial than normal, age-related changes. This was ob-
served throughout the entire retinal vasculature in the affected
eye, but not in the contralateral eye, suggesting the changes are
disease specific. In fact, thickening of vascular walls has been
previously noticed by Green et al.2 in some of the cases in their
CRVO histopathologic study.
The causes of the excessive basement membrane thicken-
ing in our case are not known. Nonetheless, endothelial cell
proliferation has been shown in BRVO animal models19,30 and
in other vasodegenerative conditions, such as diabetic retinop-
athy and radiation retinopathy.31,32 In some instances, base-
ment membrane duplication have been described,32–34 which
could have been deposited in sequence by proliferating and
dying endothelial cells35; a mechanism that may have
contributed to the basement membrane broadening in our
CRVO case. Endothelial cell turnover might also be linked to
the conversion of nonischemic to ischemic CRVO–the expan-
sion of the nonperused region. However, what sort of insults
might cause endothelial cell death in this situation is open to
speculation. Our CRVO patient had received more than 40
bevacizumab injections and it could be argued that this might
have damaged the remaining endothelium. However, clinical
evidence indicates the contrary about blocking VEGF in RVO,
where anti-VEGFs appear to be beneficial and reduce
expansion of nonperfused regions.36,37
Persistent basement membrane in vasodegeneration condi-
tions in the retinal vasculature may also have therapeutic
implications, as the remaining structures can potentially
provide a scaffold for vascular regrowth.38 Re-endothelializa-
tion of acellular basement membranes has been observed
numerous times in model systems,7,32,33,39,40 as well as in
patients.2,33 Also, reperfusion in RVO patients seems to be
promoted by anti-VEGF therapy,8,36 which is probably based
on re-endothelialization of persistent basement membranes.
Furthermore, cell therapy approaches, aiming to regenerate
ischemic retinal vasculature41,42 will depend on a persistent
extracellular template. Thus, our finding of persistent base-
ment membrane after occlusion, demonstrates that therapies
aiming for reperfusion in ischemic eye disease are possible in
principle.
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